[Is Herceptin(®) (trastuzumab) by subcutaneous a mini revolution? Pharmaco-economic study]
- PMID: 25725921
- DOI: 10.1016/j.bulcan.2015.01.007
[Is Herceptin(®) (trastuzumab) by subcutaneous a mini revolution? Pharmaco-economic study]
Abstract
Herceptin(®) injected by intravenous (IV) is one of the key treatment of breast cancer HER2+. The improvement of galenic form allowed a new way of administration, the sub-cutaneous way (SC), authorized by EMEA in 2013. This new way enables a 5-minute infusion, a fixed dose and a fixed volume of preparation. On 2012, saving-time and financial impacts were calculated by extrapolation of the IV way in a cancer treatment center. The study showed a preparing time-saving of 7.5min/loading dose and of 6.5min/maintenance dose, and a nurse time-saving of 4.5min/loading dose and 4.25min/maintenance dose. Moreover, it can be added a saving of consumable of 13,31€ per injection in case of monotherapy. The SC leads to a new adaptation and reorganization in the preparation of monoclonal antibodies and day hospitals.
Keywords: Herceptin; Pharmaco-economic; Pharmaco-économique; Sous-cutanée; Subcutaneous.
Copyright © 2015 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous